Top 10 Companies in the Global Tranilast Market (2026): Market Leaders Driving Therapeutic Innovation

In Business Insights
July 31, 2026


MARKET INTELLIGENCE OVERVIEW

Tranilast Market Insights

Tranilast, an anti‑allergic and anti‑inflammatory agent, is gaining traction across therapeutic areas such as asthma, keloid management, and emerging oncology indications. Its dual role as a direct medication and a high‑purity chemical intermediate sustains demand from both pharma manufacturers and research laboratories.

Global Tranilast Market market size was valued at USD 0.152 billion in 2025. The market is forecast to expand from USD 0.162 billion in 2026 to USD 0.260 billion by 2034, reflecting a CAGR of 6.2%. The compound annual growth rate has been refined to 6.2% for the forecast horizon.

📊
Current Market Size
152

USD Mn

2025 Value

📈
CAGR
6.2%

2026–2034

🎯
Forecast Market Size
260

USD Mn

By 2034

Strategic Market Outlook
Long-Term Industry Perspective
Tranilast’s continued relevance stems from its proven safety profile and the expanding therapeutic envelope around anti‑fibrotic interventions. As regulatory agencies grant conditional approvals for novel indications, manufacturers are positioning the 99% purity grade as the standard for API‑level production, while cost‑effective 98% grades serve niche research applications. The convergence of these supply‑side efficiencies with heightened clinical interest underpins a steady upward trajectory for the market.

🌐
Leading Region
North America

🌍
Emerging Region
Asia‑Pacific

🔟 1. Daiwa Pharmaceutical

Headquarters: Tokyo, Japan

Key Offering: API production of 99% purity Tranilast and branded anti‑allergic formulations.

Daiwa’s vertically integrated plant delivers consistent supply to both domestic and international markets, ensuring quality compliance across multiple regulatory regimes.

Key Growth Initiatives:

  • Expansion of contract‑manufacturing capacity for emerging indications.
  • Investment in advanced purification modules to sustain 99% grade output.
  • Strategic alliances with regional pharma to broaden distribution.

9️⃣ 2. Cayman Chemical

Headquarters: Wilmington, United States

Key Offering: High‑purity Tranilast for research and pharmaceutical development.

Cayman’s robust analytical platform supports rapid assay development, facilitating early‑stage drug discovery projects.

Key Growth Initiatives:

  • Launch of a dedicated API service for niche specialty drugs.
  • Partnerships with academic institutions to accelerate translational research.
  • Deployment of digital order management to improve client turnaround.

8️⃣ 3. Enzo Life Sciences

Headquarters: San Diego, United States

Key Offering: Comprehensive supply of Tranilast for laboratory and preclinical studies.

Enzo’s global distribution network and rapid batch production enable timely support for clinical trials across continents.

Key Growth Initiatives:

  • Expansion of raw‑material sourcing to reduce lead times.
  • Development of custom synthesis services for specialty chemists.
  • Investment in sustainability initiatives to lower carbon footprint.

7️⃣ 4. FUJIFILM Wako Pure Chemical Corporation

Headquarters: Tokyo, Japan

Key Offering: Ultra‑pure Tranilast for pharmaceutical manufacturers.

FUJIFILM Wako’s advanced chromatographic techniques ensure consistent batch quality, supporting high‑volume production for global clients.

Key Growth Initiatives:

  • Integration of AI‑driven process controls to optimize yield.
  • Collaboration with regulatory agencies to streamline approval pathways.
  • Expansion of the API portfolio to include related anti‑fibrotic agents.

6️⃣ 5. MANUS AKTTEVA BIOPHARMA

Headquarters: New Delhi, India

Key Offering: Custom synthesis and contract manufacturing of Tranilast for generic and specialty markets.

MANUS leverages its cost‑efficient production base to offer competitive pricing while maintaining rigorous quality controls.

Key Growth Initiatives:

  • Scaling of batch capacity to meet rising demand in emerging markets.
  • Investment in GMP upgrades to align with international standards.
  • Strategic partnership with local distributors to enhance market penetration.

5️⃣ 6. Adooq Bioscience

Headquarters: San Francisco, United States

Key Offering: Rapid‑turnaround synthesis of Tranilast for biotech firms and academic labs.

Adooq’s flexible manufacturing model supports small‑batch projects, reducing time to market for novel therapeutic candidates.

Key Growth Initiatives:

  • Development of scalable micro‑reactor platforms for high‑throughput synthesis.
  • Expansion of service offerings to include formulation development.
  • Collaboration with venture‑backed biotech companies to accelerate product pipelines.

4️⃣ 7. AOBIOUS

Headquarters: Chicago, United States

Key Offering: Specialty chemical intermediates including Tranilast for niche research applications.

AOBIOUS focuses on delivering high‑quality reagents to academic and industrial research groups, supporting early‑stage discovery.

Key Growth Initiatives:

  • Enhancement of supply chain resilience through diversified sourcing.
  • Investment in green chemistry practices to reduce waste.
  • Launch of a digital platform for order tracking and inventory management.

3️⃣ 8. LGM Pharma

Headquarters: Atlanta, United States

Key Offering: Contract manufacturing of Tranilast for generic pharmaceutical companies.

LGM’s scalable facilities and experienced regulatory team enable rapid scale‑up for emerging therapeutic indications.

Key Growth Initiatives:

  • Expansion of API production lines to accommodate higher purity grades.
  • Collaboration with regulatory consultants to expedite approvals.
  • Adoption of real‑time quality monitoring systems.

2️⃣ 9. BioChemPartner

Headquarters: Shanghai, China

Key Offering: Large‑scale synthesis of Tranilast for domestic and export markets.

BioChemPartner’s extensive raw‑material network and cost‑efficient processes support high‑volume production for regional pharma companies.

Key Growth Initiatives:

  • Investment in advanced purification technologies to achieve 99% purity output.
  • Strategic alliances with local manufacturers to broaden distribution.
  • Implementation of digital traceability systems for regulatory compliance.

1️⃣ 10. CarboMer

Headquarters: New York, United States

Key Offering: Specialty chemical services including Tranilast for pharmaceutical and industrial clients.

CarboMer’s flexible manufacturing platform supports rapid scale‑up for both research and commercial production.

Key Growth Initiatives:

  • Expansion of contract‑manufacturing capacity for emerging indications.
  • Investment in process automation to improve throughput.
  • Partnerships with global distributors to enhance market reach.

Global Tranilast Market – View in Detailed Research Report

🌍 Outlook: The Future of Tranilast Market

With a solid foundation in anti‑allergic and anti‑fibrotic indications, Tranilast is positioned to become a key therapeutic platform as new clinical evidence emerges. The convergence of expanded indications, high‑purity API availability, and cost‑effective manufacturing will sustain demand across both developed and emerging markets.

📈 Key Trends Shaping the Market

  • Broadening of therapeutic scope into oncology and cardiovascular applications.
  • Shift toward extended‑release and targeted‑delivery formulations to improve adherence.
  • Adoption of digital health tools to monitor dosing and side‑effect profiles.
  • Increased focus on sustainability and green chemistry in API production.
  • Strategic partnerships between pharma and contract manufacturers to accelerate market entry.

Global Tranilast Market – View in Detailed Research Report